Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 12/20 | 0.47 |
| ▸ | CDK8 | P49336 | 12/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481247 | 1.00 | CCNC (0.47) | CCNCCDK8AXLFYNTNK2 | |
| SCHEMBL25602473 | 0.90 | CCNC (0.52) | CCNCCDK8TTKGSK3BDYRK1A | |
| SCHEMBL31501358 | 0.90 | CCNC (0.52) | CCNCCDK8TTKGSK3BDYRK1A | |
| SCHEMBL25602471 | 0.90 | CCNC (0.47) | CCNCCDK8AXLGSK3BDYRK1A | |
| SCHEMBL31501379 | 0.90 | CCNC (0.47) | CCNCCDK8AXLGSK3BDYRK1A | |
| SCHEMBL31501393 | 0.88 | CCNC (0.47) | CCNCCDK8ALKDYRK1A | |
| SCHEMBL25602463 | 0.88 | CCNC (0.47) | CCNCCDK8ALKDYRK1A | |
| SCHEMBL31501345 | 0.85 | SCN9A (0.46) | CCNCCDK8ALKTTK | |
| SCHEMBL25602317 | 0.85 | SCN9A (0.46) | CCNCCDK8ALKTTK | |
| SCHEMBL13429174 | 0.75 | AXL (0.50) | CCNCCDK8AXLFYNALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | CCNC 921/4885CDK8 316/4885AXL 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.